COSCIENS Biopharma inks China distribution deal for Macimorelin

TL;DR

COSCIENS Biopharma just signed a big distribution deal for Macimorelin in China with Wuzhou.

AI Summary

On December 1, 2025, COSCIENS Biopharma Inc. announced an Exclusive Distribution Agreement with Wuzhou for its pharmaceutical product, Macimorelin. This agreement grants Wuzhou the rights to distribute Macimorelin in China, Hong Kong, Macau, and Taiwan. The company also reported on its financial performance and strategic initiatives.

Why It Matters

This agreement expands COSCIENS Biopharma's market reach for Macimorelin into the significant Chinese market, potentially driving future revenue growth.

Risk Assessment

Risk Level: medium — The success of this agreement depends on Wuzhou's distribution capabilities and market acceptance of Macimorelin in the specified territories.

Key Players & Entities

• COSCIENS Biopharma Inc. (company) — Registrant and party to the agreement
• Wuzhou (company) — Distributor in China, Hong Kong, Macau, and Taiwan
• Macimorelin (product) — Pharmaceutical product subject to distribution agreement
• December 1, 2025 (date) — Date of the press release and agreement announcement

FAQ

Filing Documents

• form6-k.htm (6-K) — 30KB
• ex99-1.htm (EX-99.1) — 19KB
• ex99-1_001.jpg (GRAPHIC) — 13KB
• 0001493152-25-025595.txt ( ) — 68KB

forward-looking statements

forward-looking statements. Forward-looking synergies as well as the assets, cost structure, financial position, cash flows and growth prospects of the combined company. Risks and factors that could cause actual results or outcomes to differ materially from expectations include, among others, the following: the Company’s patented technologies and value-driving products, and development thereof; the extraction, production and commercialization of active ingredients from natural sources and our ability to successfully market related products; the successful development and marketing of our oat-based pipeline products, including oat-beta glucan, avenanthramides and beta glucan from yeast, as well as such products’ capability to address unmet needs within the nutraceuticals markets; Macrilen® (macimorelin) and the Company’s plans in respect of same, including commercialization. the Company’s business strategy; the strategic decision to sunset the Company’s Amyotrophic Lateral Sclerosis (ALS), AIM Biologicals and Delayed Clearance Parathyroid Hormone (DC-PTH) programs ; the transition to a new presidential administration in the United States, including the potential use and effects of tariffs to address the administration’s policy goals, could materially impact our costs and revenues, as well as the macroeconomic framework in which we operate. the Company’s positioning in its target markets; the Company’s ability to accelerate the scale-up of PGX Technology towards commercial levels; expectations for completion of the Company’s Edmonton facility and Natex Termitz facility; pre-clinical and clinical studies and trials and their expected timing and results, including the potential to bring certain products to market following such studies and trials; the ab

View Full Filing

View this 6-K filing on SEC EDGAR